Risk factors and consequences of atrophy of the hippocampal formation in patients with manifest arterial disease: the SMART-Medea study

Risk factors and consequences of atrophy of the hippocampal formation in patients with manifest arterial disease: the SMART-Medea study - Hippocampal atrophy in patients with manifest arterial disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37630

Enrollment

420

Registered

2013-03-11

Start date

2013-12-09

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognition hippocampal atrophy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All persons still alive who participated in the baseline examination of the SMART-Medea study from 2006 through 2009.

Exclusion criteria

Exclusion criteria: Contra-indications for MR imaging (metal objects in the body, claustrophobia, pregnancy). Terminally ill or physically unable to come to the UMCU.

Design outcomes

Primary

Measure	Time frame
Outcome variables for the primary objective are 1a) hippocampal and entorhinal cortex volume at 1.5T MRI, and 1b) cognitive functioning and late-life depression after 7 years of follow-up. Outcome variables for the second objective are 2a) cognitive functioning and late-life depression, and 2b) volumes of hippocampal subfields at 7T MRI.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results